Physician profile
Robert Liao
NPI 1891786257
$1,327.36
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $37.77 · 2021: $237 · 2022: $31.48 · 2023: $13.24 · 2024: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $369 · Food and Beverage: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $368.74 |
| Food and Beverage | $267.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $488.91 | 2024 | Indigo System |
| Medtronic Vascular, INC. | $170.29 | 2019 | |
| Novo Nordisk INC | $112.85 | 2024 | Wegovy |
| Pfizer INC. | $110.09 | 2019-2023 | |
| Medtronic, INC. | $103.34 | 2021 | |
| Janssen Pharmaceuticals, INC | $84.35 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $67.15 | 2019-2021 | |
| Shockwave Medical, INC | $57.40 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $54.70 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $31.28 | 2019-2022 | |
| Itamar Medical INC | $18.62 | 2021 | |
| Integra Lifesciences Corporation | $17.59 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Liao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.